Pfizer Acquires Metsera in $10 Billion Deal Amid Competitive Bidding War

Pfizer Inc. has reached an agreement to acquire Metsera Inc., a developer of obesity drugs, for a total valuation of $10 billion. The deal, announced on November 7, 2025, comes after a heated bidding war with Danish pharmaceutical giant Novo Nordisk, which had also sought to acquire Metsera. Pfizer's offer includes an initial payment of $65.60 per share, with potential additional payments of up to $20.65 per share contingent on achieving specific milestones, bringing the total to $86.25 per share.

BioPharmaDivePfizer acquires Metsera in $10 billion deal after competitive bidding with Novo NordiskCityLabNew York TimesCNBCReuters

The bidding war began when Pfizer initially offered $4.9 billion for Metsera in September 2025. However, Novo Nordisk entered the fray with a higher unsolicited bid, prompting Pfizer to increase its offer. The competition intensified as both companies aimed to secure a foothold in the lucrative obesity drug market, which is projected to reach $100 billion by 2030. Metsera's experimental drugs, still in development, are seen as potential game-changers in the obesity treatment landscape.

Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo NordiskCityLabNew York TimesBioPharmaDiveCNBCReuters

Metsera's board ultimately favored Pfizer's offer, citing "unacceptably high legal and regulatory risks" associated with Novo's bid. The U.S. Federal Trade Commission (FTC) had raised concerns about potential antitrust violations related to Novo's proposal. In contrast, Pfizer had already secured FTC clearance for its acquisition, which played a crucial role in Metsera's decision-making process.

BioPharmaDiveCNBCCityLabReutersNew York TimesPfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk

The acquisition positions Pfizer to enhance its portfolio in the obesity treatment sector, an area where it has struggled to develop successful in-house products. Pfizer's Chief Executive Officer, Albert Bourla, has been under pressure to replenish the company's pipeline, especially following setbacks in its own obesity drug trials. Analysts suggest that Metsera's pipeline could generate significant revenue, with projections estimating up to $11 billion by 2040.

Reuters

Novo Nordisk has expressed disappointment over the outcome, stating that it would not make another bid for Metsera. The company maintains that its offer complied with antitrust laws and characterized its exit from the bidding as a strategic decision rather than a necessity. Critics of the acquisition have pointed to the high price Pfizer is paying, suggesting it is based on optimistic assumptions about Metsera's future performance.

BioPharmaDive

Pfizer expressed satisfaction with the acquisition, stating, “We are pleased that we and Metsera have agreed to these revised terms, which will provide immediate and certain value to Metsera’s shareholders.” Metsera's board has unanimously recommended that shareholders approve the deal at the upcoming meeting on November 13, 2025.

New York Times

• “We are pleased that we and Metsera have agreed to these revised terms, which will provide immediate and certain value to Metsera’s shareholders.” — Pfizer

New York Times

• “Following a competitive process and after careful consideration, Novo Nordisk will not increase its offer to acquire Metsera,” — Novo Nordisk

CNBC

• “Novo said in its statement that it believed that the structure of its offer was "compliant with antitrust laws".” — Novo Nordisk

CNBC

The acquisition is expected to close shortly after Metsera's shareholder meeting on November 13, 2025, pending final approvals. This deal marks a significant strategic move for Pfizer as it aims to establish a strong presence in the rapidly growing obesity drug market.

Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk